PT  - JOURNAL ARTICLE
AU  - ULRICH H. WEIDLE
AU  - ADAM NOPORA
TI  - Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical <em>In Vivo</em> Models
AID  - 10.21873/cgp.20265
DP  - 2021 May 01
TA  - Cancer Genomics - Proteomics
PG  - 349--368
VI  - 18
IP  - 3 Suppl
4099  - http://cgp.iiarjournals.org/content/18/3_Suppl/349.short
4100  - http://cgp.iiarjournals.org/content/18/3_Suppl/349.full
SO  - Cancer Genomics Proteomics2021 May 01; 18
AB  - In order to identify new targets and treatment modalities for clear cell renal carcinoma, we surveyed the literature with respect to microRNAs involved in this disease. In this review, we have focused on up- and down-regulated miRs which mediate efficacy in preclinical clear-cell renal carcinoma-related in vivo models. We have identified 10 up-regulated and 33 down-regulated micro-RNAs according to this criterion. As proof-of-concept, micro-RNAs interfering with VEGF (miR-205p) and mTOR (mir-99a) pathways, which are modulated by approved drugs for this disease, have been identified. miRs targeting hypoxia induced factor-2α (HIF-2α) (miR-145), E3 ubiquitinylases speckle-type POZ protein (SPOP) (miR 520/372/373) and casitas B-lineage lymphoma (CBL) (miR-200a-3p), interfere with druggable targets. Further identified miRs interfere with cell-cycle dependent kinases, such as CDK2 (miR-200c), CDK4, 6 (miR-1) and CDK4, 9 (206c). Transmembrane receptor Ral interacting protein of 76 kD (RLIP76), targeted by mir-137, has emerged as another important target for ccRCC. Additional miRs and their targets merrying further preclinical validation are discussed.